The Federal Trade Commission said on Thursday (May 23) that while brand and generic drug makers settled patent disputes more often in fiscal year 2016 than prior years, only one of the agreements met the Supreme Court’s criteria of potentially being anticompetitive. The generic drug lobby seized on the finding to urge lawmakers to back away from plans to ban such settlements. The House recently passed a bill addressing pay-for-delay settlements in a package pairing drug-pricing bills with measures to...